Abstract
Although it is now evident that microRNAs (miRNAs) play a critical regulatory role in many, if not all, pathological and physiological processes, remarkably they have only formally been recognized for less than fifteen years. These endogenously produced short non-coding RNAs have created a new paradigm of gene control and have utility as both novel biomarkers of cancer and as potential therapeutics. In this review we consider the role of miRNAs in lymphoid biology both under physiological (i.e. lymphopoiesis) and malignant (i.e. lymphomagenesis) conditions. In addition to the functional significance of aberrant miRNA expression in lymphomas we discuss their use as novel biomarkers, both as a in situ tumour biomarker and as a non-invasive surrogate for the tumour by testing miRNAs in the blood of patients. Finally we consider the use of these molecules as potential therapeutic agents for lymphoma (and other cancer) patients and discuss some of the hurdles yet to be overcome in order to translate this potential into clinical practice.
Keywords: Biomarker, Hematological malignancies, Lymphoid, Lymphoma, microRNA, ncRNA.
Current Genomics
Title:MicroRNAs in Lymphoma: Regulatory Role and Biomarker Potential
Volume: 16 Issue: 5
Author(s): Marta Fernandez-Mercado, Lorea Manterola and Charles H. Lawrie
Affiliation:
Keywords: Biomarker, Hematological malignancies, Lymphoid, Lymphoma, microRNA, ncRNA.
Abstract: Although it is now evident that microRNAs (miRNAs) play a critical regulatory role in many, if not all, pathological and physiological processes, remarkably they have only formally been recognized for less than fifteen years. These endogenously produced short non-coding RNAs have created a new paradigm of gene control and have utility as both novel biomarkers of cancer and as potential therapeutics. In this review we consider the role of miRNAs in lymphoid biology both under physiological (i.e. lymphopoiesis) and malignant (i.e. lymphomagenesis) conditions. In addition to the functional significance of aberrant miRNA expression in lymphomas we discuss their use as novel biomarkers, both as a in situ tumour biomarker and as a non-invasive surrogate for the tumour by testing miRNAs in the blood of patients. Finally we consider the use of these molecules as potential therapeutic agents for lymphoma (and other cancer) patients and discuss some of the hurdles yet to be overcome in order to translate this potential into clinical practice.
Export Options
About this article
Cite this article as:
Fernandez-Mercado Marta, Manterola Lorea and Lawrie H. Charles, MicroRNAs in Lymphoma: Regulatory Role and Biomarker Potential, Current Genomics 2015; 16 (5) . https://dx.doi.org/10.2174/1389202916666150707160147
DOI https://dx.doi.org/10.2174/1389202916666150707160147 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Epigenetics of Breast Carcinogenesis and Metastasis
Current Genomics Effect of Lithium on Neurocognitive Functioning
Current Alzheimer Research ANN-QSAR Model for Virtual Screening of Androstenedione C-Skeleton Containing Phytomolecules and Analogues for Cytotoxic Activity Against Human Breast Cancer Cell Line MCF-7
Combinatorial Chemistry & High Throughput Screening The Reciprocal Interaction: Chemotherapy and Tumor Microenvironment
Current Drug Discovery Technologies Polynucleotide Kinase as a Potential Target for Enhancing Cytotoxicity by Ionizing Radiation and Topoisomerase I Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Targeted Drug Delivery to Cancer Stem Cells through Nanotechnological Approaches
Current Stem Cell Research & Therapy p42.3 in Gastric Carcinoma: A Novel Biomarker and Promising Therapeutic Target
Letters in Drug Design & Discovery Intravenous Immunoglobulin as a Potential Therapy for Refractory Urticaria - A Review
Inflammation & Allergy - Drug Targets (Discontinued) Novel Treatment of Acute Promyelocytic Leukemia: As<sub>2</sub>O<sub>3</sub>, Retinoic Acid and Retinoid Pharmacology
Current Pharmaceutical Biotechnology Nanotechnology, A Tool for Diagnostics and Treatment of Cancer
Current Topics in Medicinal Chemistry Functionalized Nanocarriers for Enhanced Bioactive Delivery to Squamous Cell Carcinomas: Targeting Approaches and Related Biopharmaceutical Aspects
Current Pharmaceutical Design Protein Kinase A (PKA) - A Potential Target for Therapeutic Intervention of Dysfunctional Immune Cells
Current Drug Targets Histone Deacetylase Inhibitors: From Chromatin Remodeling to Experimental Cancer Therapeutics
Current Medicinal Chemistry New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets Cancer Multitarget Pharmacology in Prostate Tumors: Tyrosine Kinase Inhibitors and Beyond
Current Medicinal Chemistry An Interventional Pulmonologist’s Tool: Endobronchial Ultrasound- Guided Transbronchial Needle Aspiration (EBUS-TBNA) in Thoracic Disease — An Update
Current Respiratory Medicine Reviews Reactive Oxygen Species in Cancer Biology and Anticancer Therapy
Current Medicinal Chemistry Parenteral Drug Delivery: A Review
Recent Patents on Drug Delivery & Formulation Nanotechnology for Nanomedicine and Delivery of Drugs
Current Pharmaceutical Design Cordycepin Suppresses Integrin/FAK Signaling and Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry